Trevi Therapeutics Advances Toward Key Regulatory Review Following Clinical Validation

Trevi Therapeutics US89532M1018

Shares of Trevi Therapeutics saw a notable advance, gaining over 6%, following a significant clinical validation milestone. The company's detailed Phase 2b data for its lead candidate, Nalbuphine ER (Haduvio), has been published in the prestigious Journal of the American Medical Association (JAMA). This peer-reviewed publication strengthens the biopharmaceutical firm's position ahead of pivotal upcoming discussions with regulators.

The CORAL study investigated the drug's efficacy in treating chronic cough associated with idiopathic pulmonary fibrosis (IPF). Results demonstrated a statistically significant reduction in cough frequency compared to a placebo, with the therapeutic effect beginning as early as the second week of treatment. By the sixth week, more than 60% of patients achieved at least a 50% reduction in coughing episodes.

A critical factor for the impending regulatory pathway is the compound's safety and tolerability profile. The data revealed a discontinuation rate due to adverse events of 5.6% in the treatment groups, comparable to the 5.0% rate observed in the placebo group. Notably, serious adverse events occurred less frequently in patients receiving the medication. Common side effects, including nausea and dizziness, were consistent with expectations for this class of drug and were reported to be generally well-tolerated.

The therapy targets a substantial unmet medical need. In the United States alone, an estimated 100,000 out of approximately 150,000 IPF patients suffer from the debilitating chronic cough condition, for which there is currently no approved treatment.

Financial Runway Supports Late-Stage Development

Trevi Therapeutics enters this next stage from a position of financial strength. The company reports a solid cash position of approximately $195 million, which it states provides sufficient funding to advance its clinical programs into 2028. Recent executive appointments, including a new Chief Financial Officer, underscore preparations for this late-phase development and potential commercialization efforts.

Upcoming Catalysts Define the Path Forward

The immediate corporate focus is on a clear regulatory and clinical timeline. Trevi plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) within the current quarter. This dialogue is expected to define the design of the crucial Phase 3 trial, which is slated to commence in the first half of 2026. Concurrently, the company is preparing an additional Phase 2b study for refractory chronic cough (RCC). The outcome of the FDA meeting in Q1 is anticipated to be a primary driver for the stock's near-term performance.